In summary, in the treatment of high-risk CVD patients, the combination of astatin and a PCSK9 inhibitor was safe and more effective in lowering lipid levelsand achieving the target than other rosuvastatin-based regimens, while theaddition of ezetimibe was unable to significantly lower lipid levels any further.The rate of achieving the target was higher in patients with hypertension and lowBMI. This evidence concerns the gene PCSK9 and Hypertension.